ASCO® GI 2025 Insights: Camrelizumab + Rivoceranib vs. Sorafenib for 1L Unresectable HCC of Viral and Non-Viral Etiology - Ph3 CARES-310 Trial | VuMedi

Find latest Hepatocellular Cancer videos · 200+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

This video is featured in the Insights from 2025 ASCO® GI Annual Meeting

Insights from 2025 ASCO® GI Annual Meeting

ASCO® GI 2025 Insights: Camrelizumab + Rivoceranib vs. Sorafenib for 1L Unresectable HCC of Viral and Non-Viral Etiology - Ph3 CARES-310 Trial

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Rachna Shroff

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Rachna Shroff

66 views

February 25, 2025

Comments 0

Login to view comments. Click here to Login